NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,000 | -99.5% | 200 | -98.4% | 0.00% | -98.9% |
| Q1 2020 | $218,000 | -19.9% | 12,200 | -3.2% | 0.09% | -9.0% |
| Q4 2019 | $272,000 | +13.8% | 12,600 | -3.8% | 0.10% | +20.5% |
| Q3 2019 | $239,000 | -52.4% | 13,100 | -7.1% | 0.08% | -51.5% |
| Q2 2019 | $502,000 | +5.9% | 14,100 | 0.0% | 0.17% | +8.9% |
| Q1 2019 | $474,000 | +20.3% | 14,100 | +17.5% | 0.16% | +15.4% |
| Q4 2018 | $394,000 | -46.2% | 12,000 | 0.0% | 0.14% | -33.7% |
| Q3 2018 | $732,000 | +24.9% | 12,000 | 0.0% | 0.20% | +19.2% |
| Q2 2018 | $586,000 | -54.0% | 12,000 | 0.0% | 0.17% | -53.5% |
| Q1 2018 | $1,275,000 | +77.8% | 12,000 | 0.0% | 0.37% | +86.9% |
| Q4 2017 | $717,000 | +149.0% | 12,000 | 0.0% | 0.20% | +120.0% |
| Q3 2017 | $288,000 | – | 12,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |